文献リスト

1) Angus PW, Patterson SJ. Liver transplantation for hepatitis B: What is the best hepatitis B immune globulin/antiviral regimen？ Liver Transplantation. 2008; 14: S15-S22

2) Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007; 132: 931-7

3) Takaki A, Yagi T, Iwasaki Y, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation. 2007; 83: 231-3

4) Hooman N, Rifai K, Hadem J, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl. 2008; 14: 435-42

5) Hussain M, Soldevia-Pico C, Emre S, et al. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl. 2006; 12: 253-8

6) Buti M, Mas A, Prieto M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation. 2007; 84: 650-4

7) Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci. 2007; 52: 2497-500

8) Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007; 13: 349-60

9) Borrotto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol. 2007; 47: 492-8

10) Qi X, Xiong S, Yang H, et al. In vitro susceptivility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007; 12: 355-62

11) Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatits B. Hepatology. 2007; 45: 307-13

12) Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007; 133: 1445-51

13) Lo CM, Lau GK, Chan SC, et al. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant. 2007; 7: 434-9

14) Luo Y, Lo CM, Cheung CK, et al. Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Taranspl. 2007; 13: 71-9

15) 日本肝移植研究会. 肝移植症例登録報告. 移植. 2008; 43: 45-55

16) Ramires S, Perez-del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 2008; 14: S27-35

17) Gawrieh S, Papouchado BG, Burgart LJ, et al. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2005; 11: 1207-13

18) Russo MW, Firpi RJ, Nelson DR, et al. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl. 2005; 11: 1235-41

19) Schulze-Krebs A, Preimel D, Popov Y, et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology. 2005; 129: 246-58

20) Bataller R, Paik YH, Lindquist JN, et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004; 126: 529-40

21) Mazzocca A, Sciammetta SC, Carloni V, et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem. 2005; 280: 11329-39

22) Wise M, Bialek S, Finelli L, et al. Changing trends in HCV-related mortality in USA. Hepatology. 2008; 47: 1372-80

23) Saraf N, Fiel MI, Deboccardo G, et al. Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation. Liver Transpl. 2007; 13: 913-7

24) Yilmaz N, Shiccman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent HCV following liver transplantation. Liver Transpl. 2007; 13: 975-83

25) Belli L, Burroughs A, Burra P. Liver transplantation for HCV-cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long-term retrospective study. Liver Transpl. 2007; 13: 733-40

26) Baiocchi L, Angelico M, Petrolati A, et al. Correlation between liver fibrosis and inflammation in patients transplanted for HCV-liver disease. Am J Transplant. 2008; 8: 673-8

27) McCashland T, Watt K, Lyden E, et al. Retransplantation for HCV: results of a US multicentre retransplant study. Liver Transpl. 2007; 12: 1246-53

28) Ghabril M, Dickson R, Wiesner R. Improving outcomes in retransplantation: an analysis of trends and the impact of HCV infection. Am J Transplant. 2008; 8: 404-11

29) Thuluvath P, Krok K, Segev D, et al. Trends in post transplant survival in patients with HCV between 1991 and 2001 in the United States. Liver Transpl. 2007; 13: 719-24

30) Schvoerer E, Soulier E, Royer C. Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. JID. 2007; 196: 528-36

31) Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation. 2007; 84: 829-35

32) Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(＋) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl. 2007; 13: 1521-31

33) Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol. 2007; 47: 793-8

34) Hirano K, Ichikawa T, Nakao K, et al. Differential effects of tacrolimus and cyclosporine on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl. 2008; 14: 265-7

35) Briceno J, Ciria R, Pleguezuelo M, et al. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc. 2007; 39: 2297-9

36) Yagci G, Fernandez LA, Knechtle SJ, et al. The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. Transplant Proc. 2008; 40: 219-23

37) Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs deceased donor liver transplantation. Liver Transpl. 2007; 13: 122-9

38) Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008; 14: S58-66

39) Zimmermann T, Bocher WO, Biesterfeld S, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007; 20: 583-90

40) Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008; 49: 274-87

41) Berenguer M, Palau A, Aguilera V, Rayon JM, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008; 8: 679-87

42) Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to anti-viral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007; 46: 459-65

43) Lodato F, Berardi S, Gramenzi A, et al. Peg-interferon alfa-2b and ribavirin for the treatment of genotype 1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther. 2008; 28: 450-7

44) Hanouneh IA, Miller C, Aucejo F, et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl. 2008; 14: 53-8

45) Sherma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl. 2007; 13: 1100-8

46) Stanca CM, Fiel MI, Kontorinis N, et al. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation. 2007; 84: 180-6

47) Berardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis？ Gut. 2007; 56: 237-42

48) Carrion JA, Navasa M, Garcia-Retorillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 132: 1746-56

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp